Research Comparison
Semaglutide vs Tirzepatide
A side-by-side research comparison of Semaglutide and Tirzepatide drawn from Cobalt Peptides' peptide database records.
Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is acylated with a C18 fatty diacid through a γ-glutamyl spacer, which promotes albumin binding and extends its half-life to approximately seven days. The published literature describes GLP-1 receptor activation with downstream effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing semaglutide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.
Tirzepatide
Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Engaging both incretin receptors is what distinguishes it from GLP-1-only compounds, and the published literature describes effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing tirzepatide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.